Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vytrus BiotechFRA:V5P -3.25%66 3-Year ROIIC % is 67.30 as of Dec. 2025, which is 187% above its 10-year median of 23.41. GuruFocus rates FRA:V5P with a GF Score™ of 66/100 and a GF Value™ of €6.84 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, Vytrus Biotech ranks better than 75.11% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Vytrus Biotech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 67.30%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Vytrus Biotech's 3-Year ROIIC % or its related term are showing as below:
FRA:V5P's 3-Year ROIIC % is ranked better than 75.11% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs FRA:V5P: 67.30
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Vytrus Biotech 3-Year ROIIC % Related Terms
Vytrus Biotech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:V5P vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Vytrus Biotech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's 3-Year ROIIC % falls into.
Vytrus Biotech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 2.9487594 (Dec. 2025) - 0.645 (Dec. 2022) )
/
( 10.652 (Dec. 2025) - 7.229 (Dec. 2022) )
=
2.3037594
/
3.423
=
67.30%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Vytrus Biotech (FRA:V5P) has a 3-Year ROIIC % of 67.30 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Vytrus Biotech and its competitors. This is 187% above median its historical median of 23.41. Over the past decade, Vytrus Biotech's 3-Year ROIIC % has ranged from 10.64 to 67.30. According to the industry distribution chart, Vytrus Biotech ranks #329 out of 1322 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Vytrus Biotech's 3-Year ROIIC % too high?
Vytrus Biotech's current 3-Year ROIIC % of 67.30 is 187% above median its 10-year median of 23.41. Over the past 10 years, this metric has ranged from a low of 10.64 to a high of 67.30. Based on the distribution chart, Vytrus Biotech ranks #329 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #329 out of 1322 companies for 3-Year ROIIC %. This places Vytrus Biotech in the top 25% of its industry — outperforming the majority of peers. Historically, Vytrus Biotech's own 3-Year ROIIC % has ranged from 10.64 to 67.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Vytrus Biotech and its competitors. Vytrus Biotech's current 3-Year ROIIC % is 67.30, which is 187% above median its own 10-year median of 23.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (FRA:V5P) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.84, compared to a current price of €16.35 — trading 139% above its estimated fair value. The current 3-Year ROIIC % is 67.30, which is 187% above median its 10-year median of 23.41. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Vytrus Biotech (FRA:V5P), the current 3-Year ROIIC % is 67.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €16.35 is trading 139% above its estimated GF Value™ of €6.84.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for FRA:V5P:
3-Year ROIIC %: 67.30 (187% above median its 10-year median of 23.41)
GF Value™: €6.84 vs. price of €16.35 (139% above fair value)
No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score
Get the complete analysis for FRA:V5P
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V5P has been successfully added to your 
